PRISM MediaWire

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway

27 August 2024

Halberd Corp. Issues Letter to Shareholders

Jackson Center, PA, August 26, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders:

26 August 2024

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

Successful Conversion Eliminates Over $4 Million in Long-Term Debt

26 August 2024

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

· Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouth

22 August 2024

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Study Evaluating the Value of Vendaje® Compared to the Standard of Care for Non-Healing Diabetic Foot Ulcers

Study supports BioStem’s strategic growth initiatives and accelerates product adoption by providing data to healthcare professionals and payers on the benefits of Vendaje

21 August 2024

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

· LP-20 contrast agent designed to diagnose interstitial cystitis and detect bladder cancer

21 August 2024

ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)

New York, NY. August 21, 2024 - PRISM MediaWire - ANEW MEDICAL, INC. (“ANEW” or the “Company”) (NASDAQ: WENA), announced the signing of an exclusive worldwide license agreement with Transfertech Sherbrooke (“TTS”) regarding Nanoject, a needle-free, freeze-dried nanopowde...

21 August 2024

ANEW MEDICAL, INC. Appoints New CFO

New York, NY, August 19, 2024 - PRISM MediaWire - ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.-based biotechnology company focused on developing cell and gene-based treatments for aging, and age-related diseases, today announced the appointment of ...

19 August 2024

ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases

Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW’s IP for development and commercialization in the U.S.

15 August 2024

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure

12 August 2024